We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cancer Research UK Selects Eden Biodesign to Develop and Manufacture two Therapeutic Candidates
News

Cancer Research UK Selects Eden Biodesign to Develop and Manufacture two Therapeutic Candidates

Cancer Research UK Selects Eden Biodesign to Develop and Manufacture two Therapeutic Candidates
News

Cancer Research UK Selects Eden Biodesign to Develop and Manufacture two Therapeutic Candidates

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cancer Research UK Selects Eden Biodesign to Develop and Manufacture two Therapeutic Candidates"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eden Biodesign Ltd has announced that it has signed agreements with Cancer Research UK (CR-UK) to provide consultancy, process development and manufacturing services for two of CR-UK’s gene therapy products: AdhTR- NTR for advanced intra-abdominal cancer and Ad.CP62 for head and neck cancer.

Ad-hTR-NTR is a telomerase targeted adenoviral suicide gene therapy vector, which is active in telomerase expressing cancer cells. Activation of the hTR promoter in cancer cells drives bacterial nitroreductase expression and converts the inactive prodrug CB1954 into its active form leading to cell death.

Ad.CPG2 is a conditionally replication-competent oncolytic adenovirus that expresses carboxypeptidase G2 (Ad.CPG2). Activation of the prodrug (ZD2767P) by CPG2 releases a potent alkylating mustard preventing tumour proliferation by DNA cross-linking.

Under the terms of the agreements, Eden Biodesign will provide strategic advice to produce an effective development plan that will optimize the preclinical process with a view to expediting clinical manufacture and supply.

Eden Biodesign will also develop the manufacturing process and associated analytical testing for these therapies. Depending on achieving preclinical development milestones, Eden Biodesign will provide cGMP (current Good Manufacturing Practices) production of Ad-hTR-NTR and Ad.CPG2 for the Phase I clinical trials. The complete project could take up to 18 months and reach £1.5 million in value.

The development work will take place primarily at the UK National Biomanufacturing Centre which is run by Eden Biodesign.

Advertisement